Skip to main content
Premium Trial:

Request an Annual Quote

Indiana Start-Up Licenses Purdue's pRNA Tech for Drug Development

NEW YORK (GenomeWeb News) — Indiana-based start-up Kylin Pharmaceuticals has licensed the rights to use more than 12 RNAi-related patents from the Purdue Research Foundation to develop drugs, the Foundation said today.
Kylin has received start-up capital from the Indiana venture group IN-vivo Ventures, and from the Research Triangle Park, NC-based Golden Pine Ventures. The company initially plans to focus its efforts on developing therapeutics for cancer, and for viral diseases such as AIDS later.
The Foundation said the pRNA technology it has licensed to Kylin can be used to help deliver targeted RNA-based therapeutics at certain genes.
The IP was invented and developed by a former Purdue professor Peixuan Guo, who is now a director of the Nanomedicine Bionanotechnology Center at the University of Cincinnati. Guo is one of Kylin’s founders and is chairman of the company’s scientific advisory board.
Financial terms of the agreement were not released.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.